Phase I study for high dose hypofractionated radiotherapy in early stage glottic cancer
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0001805
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
A. Age: 20 years or older.
B. Histologically confirmed squamous cell carcinoma in vocal cords
C. Clinical stage T1-2N0M0
D. Performance status: ECOG 0-2, KPS 50-100
E. Decided to participate in this clinical trial voluntarily, and signed the written informed consent
Exclusion Criteria
A. Prior neck radiotherapy
B. Palliative aim
C. Involved in posterior commissure
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Toxicity
- Secondary Outcome Measures
Name Time Method Quality of life;Tumor response
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie high dose hypofractionated radiotherapy in early glottic cancer?
How does high dose hypofractionated radiotherapy compare to conventional radiotherapy in treating T1-T2 glottic cancer?
Are there specific biomarkers associated with response to hypofractionated radiotherapy in laryngeal squamous cell carcinoma?
What are the acute and late adverse events of high dose hypofractionated radiotherapy in early stage glottic cancer patients?
What are the current combination strategies involving hypofractionated radiotherapy for head and neck cancers?